使用Pycnogenol®进行慢性莱姆病的补充治疗
Maria R Cesarone1, Shu Hu1, Gianni Belcaro2
1IRVINE3 Labs, Chieti-Pescara, Italy.
Minerva medica
|May 15, 2025
概括
补充Pycnogenol (Pycnogenol®) 安全地减少了持续性莱姆病患者的炎症和症状. 这项研究显示了其在治疗慢性炎症疾病方面的潜力.
科学领域:
- 综合医学是一个整体的医学.
- 自然产品研究自然产品研究
- 炎症生物学 炎症生物学
背景情况:
- 莱姆病 (阶段2-3) 的持续症状缺乏特定的治疗方法.
- 调查慢性莱姆病的抗炎补充剂至关重要.
- Pycnogenol®是一种抗炎补充剂,具有潜在的治疗应用.
研究的目的:
- 评估Pycnogenol®在降低莱姆病患者的炎症和缓解症状方面的疗效.
- 评估Pycnogenol®补充剂的安全性和耐受性.
- 探索Pycnogenol®对氧化应激标志物和炎症指标的影响.
主要方法:
- 一项为期六个月的试点注册研究,涉及40名患有持续莱姆病症状的受试者.
- 两组:Pycnogenol® (150毫克/天) 加标准护理与单独标准护理.
- 使用了临床评估,血氧化应激测量,超声波和红细胞沉率 (ESR).
主要成果:
- 补充Pycnogenol®的耐受性很好,没有报告的副作用.
- 在Pycnogenol®组中观察到症状频率和强度的显著减少.
- 与对照组相比,在Pycnogenol®组中发现了血氧化应激,膝盖输液和ESR的减少.
结论:
- 六个月的Pycnogenol®摄入有效地缓解了持续的莱姆病症状.
- 该补充剂表现出抗炎和抗氧化特性,有助于控制慢性炎症.
- 皮克诺日 (Pycnogenol®) 提供了一种安全有效的选择,用于管理莱姆病的慢性炎症过程.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Management of Insomnia
235
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
235
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Pneumonia IV: Management
311
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
311


